Age

18–any

Sex

ALL

Healthy volunteers

Not accepted

Histologically confirmed diagnosis of NSCLC adenocarcinoma stage IV or unresectable stage III.
Have measurable disease based on RECIST 1.1.
Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
Adequate organ function.

Tracking T-Cell Responses to Evaluate Pembrolizumab Effectiveness in Advanced Non-Small Cell Lung Cancer